This phenomenon, named excitotoxicity, has also been implicated in epileptic seizures and various chronic and progressive neurodegenerative diseases, such as Huntington’s chorea, Alzheimer’s disease, and Parkinson’s disease. Injury (trauma or ischemia) in the brain triggers an abnormal release of glutamate and other excitatory aminoacids that contribute significantly to neuronal death. These results indicate that the nucleotides included in Nucleo CMP Forte ® are promising therapeutic molecules for the prevention of neuronal death in brain caused by focal ischemia, Parkinson’s disease or other neurodegenerative pathologies. More interestingly, drug pre-treatment significantly reduced MPP +- and glutamate-induced cell death in SH-SY5Y cells and in rat cortical cells. Nucleo CMP Forte ® pre-treatment significantly increased the rate of cell division in SH-SY5Y cells, as well as the synthesis of triglycerides and phospholipids. Cell viability was measured at different times.
We used the human dopaminergic cell line SH-SY5Y and a primary culture of rat cortical cells pre-treated with the drug for 24 hours and then exposed to MPP + or glutamate at a range of concentrations. We examined its neuroprotective effects on cell toxicity induced by glutamate excitotoxicity or by 1- methyl-4-phenyl-pyridinium (MPP +), an in vitro cell model of Parkinson’s disease. Its effects on brain pathologies has received little attention. It has been prescribed for peripheral nervous system disorders, such as lumbosciatalgia, diabetic or alcoholic polyneuropathy, or trigeminal neuralgia. Nucleo CMP Forte ® is a nucleotide-based drug consisting of cytidinemonophosphate, uridinemonophosphate, uridinediphosphate and uridinetriphosphate. Keywords: Cortical Cell Culture, Nucleotides, Excitotoxicity, Glutamate Neuroprotection, Parkinson’s Disease, SH-SY5Y Cells
Armadin (mexidol) solution for injections 50 mg/ml.Keep out of the reach of children at a temperature not exceeding 30 ° C.
In case of an adverse reaction caused by the use of the drug, consult your doctor. Individuals with hypersensitivity may experience allergic reactions, including rash, itching of the skin, flushing of the skin. Given the low toxicity of the drug, the likelihood of poisoning is low even if the therapeutic dose is accidentally exceeded. If necessary, taking the capsules as prescribed by the doctor can be extended by 20 days. The recommended course of treatment is at least 10 days. Forte should be taken before or after meals. There are no adequate data from the use of the drug in children. Not established, except for known allergic reactions to certain components of the drug.
Facial, trigeminal neuralgia, intercostal neuralgia, lumbago. Treatment of bone and joint neuropathies (sciatica, radiculitis), metabolic (alcoholic, diabetic polyneuropathy), infectious origin (shingles). Forte contains nucleotides: cytidine monophosphate (CMF), uridine triphosphate (UTP) – which are widely used to treat diseases of the central nervous system (CNS). Active ingredients: Cytidine-5-disodium monophosphate (CMP disodium salt), uridine-5-trisodium triphosphate (UTP trisodium salt), uridine-5-disodium diphosphate (UDP disodium salt), uridine-5 disodium monophosphate (UMP disodium salt) ġ capsule contains cytidine-5-monophosphate disodium salt (CMP disodium salt) 5 mg uridine-5-triphosphate trisodium salt (UTP trisodium salt), uridine-5-diphosphate disodium salt (UDP disodium salt), uridine-5-monophosphate salt (UMF disodium salt) only 3 mg (equivalent to 1.330 mg of pure uridine)Įxcipients: citric acid, sodium, magnesium stearate, colloidal silicon dioxide, beckons (E 421).
0 kommentar(er)
